Abstract
Incretins have improved the management of obesity and its related complications, but maintaining these health benefits requires ongoing administration, which can be challenging. Orforglipron, a once-daily oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated weight loss efficacy, improvements in cardiometabolic risk factors, and safety generally similar to inj...
**ACADEMIC MODE**
**Methodology Check:** The study employs a rigorous double-blind, placebo-controlled design with clear primary and secondary endpoints. However, the absence of a comparator arm continuing injectable therapy limits direct comparisons between oral and injectable maintenance strategies. The one-year duration, while sufficient for initial efficacy assessment, may not capture long-term adherence or metabolic adaptations. Sample sizes (N=205 and N=171) are adequate for statistical po...